CLAIMS

1. Use of a parenteral formulation of esmolol hydrochloride in the manufacture of a medicament for the treatment of a patient suffering from tachycardia comprising a ready-to-use i.v. solution of esmolol hydrochloride at a concentration of 20-100 mg/ml, which is reconstituted from a lyophilized powder consisting of at least 95% purity esmolol hydrochloride with a solvent, and wherein said solvent is an i.v. solvent devoid of alcohol or a buffer excipient, selected from the group consisting of water for injection (WFI), glucose solution, glucose and Ringer solution, glucose and saline solution, saline solution, Ringer Lactate solution or Ringer Lactate and saline solution, and said i.v. solution is to be directly administered to the patient.

2. The use according to claim 1, wherein said i.v. solution has a pH of 4.5 to 5.0.

3. The use according to claim 1 or 2, wherein said esmolol hydrochloride concentration is at least 50 mg/mL.

4. The use according to any of claims 1 to 3, wherein said i.v. solution is to be administered as continuous infusion.

5. The use according to any of claims 1 to 4, wherein said i.v. solution is to be administered as maintenance infusion at a dose of at least 25 µg/kg/min, optionally following an initial infusion at a dose of at least 300 µg/kg/min.

6. The use according to any of claims 1 to 5, wherein said i.v. solution is local tissue tolerant at the infusion site, preventing local venous irritation or skin necrosis at the infusion site.

7. The use according to any of claims 1 to 6, wherein said patient is

a. suffering from any of acute tachycardia selected from supraventricular tachycardia, ventricular tachycardia or hypertension and non-compensatory sinus

tachycardia, atrial fibrillation, atrial flutter in perioperative, postoperative, or other circumstances where short-term control of the ventricular rate is desirable, or
b. in need of blood pressure lowering during aortic dissection or for controlled hypotension to avoid blood loss in ear/ nose/ throat surgery or for diagnostic purposes.

8. The use according to any of claims 1 to 7, wherein said patient is having cardiac decompensation or hyperhydration or renal decompensation or hypernatremia or hyperchloramic acidosis.

9. The use according to any of claim 1 to 7, wherein said patient is having cardiac decompensation and hyperhydration and renal decompensation and hypernatremia and hyperchloramic acidosis.

10. The use according to any of claims 1 to 7, wherein said patient is having cardiac decompensation and any of hyperhydration, renal decompensation, hypernatremia or hyperchloramic acidosis.

11. The use according to any of claims 1 to 7, wherein said patient is having cardiac decompensation, hyperhydration and any of renal decompensation, hypernatremia or hyperchloramic acidosis.

12. The use according to any of claims 1 to 7, wherein said patient is having cardiac decompensation, hyperhydration, renal decompensation and any of hypernatremia or hyperchloramic acidosis.

13. The use according to any of claims 1 to 7, wherein said patient is having hyperhydration and any of renal decompensation, hypernatremia, hyperchloramic acidosis, or cardiac decompensation.

14. The use according to any of claims 1 to 7, wherein said patient is having hyperhydration, renal decompensation and any of hypernatremia, hyperchloramic acidosis or cardiac decompensation.

15. The use according to any of claims 1 to 7, wherein said patient is having hyperhydration, renal decompensation, hypernatremia and any of hyperchloramic acidosis or cardiac decompensation.

16. The use according to any of claims 1 to 7, wherein said patient is having renal decompensation and any of hypernatremia, hyperchloramic acidosis, cardiac decompensation or hyperhydration.

17. The use according to any of claims 1 to 7, wherein said patient is having renal decompensation, hypernatremia and any of hyperchloramic acidosis, cardiac decompensation or hyperhydration.

18. The use according to any of claims 1 to 7, wherein said patient is having hyperchloramic acidosis and any of cardiac decompensation, hyperhydration, renal decompensation or hypernatremia.

19. Ready-to-use i.v. solution containing a parenteral formulation of reconstituted lyophilized esmolol hydrochloride at a concentration of 20-100 mg/mL obtained from at least 95% purity lyophilized esmolol hydrochloride in an infusion device.

20. Ready-to-use i.v. solution comprising a parenteral formulation of at least 95% purity reconstituted lyophilized esmolol hydrochloride at a concentration of 20-100 mg/mL obtained from at least 95% purity lyophilized esmolol hydrochloride, WFI and/or saline solution, devoid of any alcohol or buffer excipients.

21. Ready-to-use i.v. solution consisting of at least 95% purity reconstituted lyophilized esmolol hydrochloride at a concentration of 20-100 mg/mL obtained from at least 95% purity lyophilized esmolol hydrochloride, WFI and optionally saline.